Sou Hu Cai Jing·2025-08-08 11:45Group 1 - The core viewpoint of the articles highlights the performance and valuation of Spring Medical, which has a closing price of 22.55 yuan and a rolling PE ratio of 67.65 times, significantly higher than the industry average of 55.70 times [1][2] - Spring Medical's total market capitalization is reported at 8.649 billion yuan, with an increase in shareholder accounts to 7,167, reflecting a rise of 501 accounts [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, with key products including spinal, trauma, joint, sports medicine implants, and surgical instruments [1] Group 2 - For the first quarter of 2025, Spring Medical achieved an operating revenue of 230 million yuan, representing a year-on-year growth of 3.60%, and a net profit of 58.0711 million yuan, with a year-on-year increase of 5.20% [1] - The gross profit margin for the company stands at 66.69%, indicating strong profitability within its operations [1] - The company has been recognized as a champion enterprise in the artificial joint prosthesis manufacturing sector by the Ministry of Industry and Information Technology in 2024 [1]